Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma

Conditions:   Renal Medullary Carcinoma;   Other Disorders of Kidney and Ureter
Interventions:   Drug: Nivolumab;   Drug: Ipilimumab
Sponsors:   M.D. Anderson Cancer Center;   Bristol-Myers Squibb
Not yet recruiting - verified September 2017

http://ift.tt/2xOmpXj